Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Leber

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Leukemia Research|October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSHeather A Leitch, Rena Buckstein, Nancy Zhu, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Annals of Hematology|February 22, 2022
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromesEugene Brailovski, Qing Li, Ning Liu, et al.
British Journal of Haematology|June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studiesMichael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
British Journal of Haematology|September 12, 2023
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) studyMaria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, et al.
British Journal of Haematology|September 8, 2021
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseDennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G Atenafu, et al.
Cell Reports. Medicine|July 11, 2023
Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemiaAllison L Boyd, Justin Lu, Cameron G Hollands, et al.
Cell Chemical Biology|June 27, 2017
Sam68 Allows Selective Targeting of Human Cancer Stem CellsYannick D Benoit, Ryan R Mitchell, Ruth M Risueño, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Blood|June 21, 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibTimothy P Hughes, Jeffrey H Lipton, Nelson Spector, et al.
Leukemia Research|October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSHeather A Leitch, Rena Buckstein, Nancy Zhu, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Annals of Hematology|February 22, 2022
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromesEugene Brailovski, Qing Li, Ning Liu, et al.
British Journal of Haematology|June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studiesMichael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
British Journal of Haematology|September 12, 2023
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) studyMaria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, et al.
British Journal of Haematology|September 8, 2021
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseDennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G Atenafu, et al.
Cell Reports. Medicine|July 11, 2023
Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemiaAllison L Boyd, Justin Lu, Cameron G Hollands, et al.
Cell Chemical Biology|June 27, 2017
Sam68 Allows Selective Targeting of Human Cancer Stem CellsYannick D Benoit, Ryan R Mitchell, Ruth M Risueño, et al.
Pageof 13